AU2012340869B2 - Thienopyrimidine inhibitors of atypical protein kinase C - Google Patents

Thienopyrimidine inhibitors of atypical protein kinase C Download PDF

Info

Publication number
AU2012340869B2
AU2012340869B2 AU2012340869A AU2012340869A AU2012340869B2 AU 2012340869 B2 AU2012340869 B2 AU 2012340869B2 AU 2012340869 A AU2012340869 A AU 2012340869A AU 2012340869 A AU2012340869 A AU 2012340869A AU 2012340869 B2 AU2012340869 B2 AU 2012340869B2
Authority
AU
Australia
Prior art keywords
optionally substituted
nr22r23
membered
nr24c
membered heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012340869A
Other languages
English (en)
Other versions
AU2012340869A1 (en
Inventor
Bruce D. Dorsey
Keith S. Learn
Emma L. MORRIS
Gregory R. Ott
Jonathan R. ROFFEY
Christelle N. SOUDY
Jason C. Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2012340869A1 publication Critical patent/AU2012340869A1/en
Assigned to IGNYTA, INC., CANCER RESEARCH TECHNOLOGY LIMITED reassignment IGNYTA, INC. Request for Assignment Assignors: CANCER RESEARCH TECHNOLOGY LIMITED, CEPHALON, INC.
Assigned to CANCER RESEARCH TECHNOLOGY LIMITED reassignment CANCER RESEARCH TECHNOLOGY LIMITED Request for Assignment Assignors: CANCER RESEARCH TECHNOLOGY LIMITED, IGNYTA, INC.
Application granted granted Critical
Publication of AU2012340869B2 publication Critical patent/AU2012340869B2/en
Priority to AU2017203725A priority Critical patent/AU2017203725B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012340869A 2011-11-23 2012-11-19 Thienopyrimidine inhibitors of atypical protein kinase C Active AU2012340869B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017203725A AU2017203725B2 (en) 2011-11-23 2017-06-02 Thienopyrimidine inhibitors of atypical protein kinase C

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563310P 2011-11-23 2011-11-23
US61/563,310 2011-11-23
PCT/US2012/065831 WO2013078126A1 (en) 2011-11-23 2012-11-19 Thienopyrimidine inhibitors of atypical protein kinase c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017203725A Division AU2017203725B2 (en) 2011-11-23 2017-06-02 Thienopyrimidine inhibitors of atypical protein kinase C

Publications (2)

Publication Number Publication Date
AU2012340869A1 AU2012340869A1 (en) 2014-06-19
AU2012340869B2 true AU2012340869B2 (en) 2017-03-02

Family

ID=47295200

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012340869A Active AU2012340869B2 (en) 2011-11-23 2012-11-19 Thienopyrimidine inhibitors of atypical protein kinase C
AU2017203725A Active AU2017203725B2 (en) 2011-11-23 2017-06-02 Thienopyrimidine inhibitors of atypical protein kinase C

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017203725A Active AU2017203725B2 (en) 2011-11-23 2017-06-02 Thienopyrimidine inhibitors of atypical protein kinase C

Country Status (11)

Country Link
US (3) US9604994B2 (OSRAM)
EP (2) EP3048106B1 (OSRAM)
JP (1) JP6206926B2 (OSRAM)
CN (1) CN104053661B (OSRAM)
AU (2) AU2012340869B2 (OSRAM)
CA (1) CA2855446C (OSRAM)
ES (1) ES2575143T3 (OSRAM)
IL (1) IL232559B (OSRAM)
IN (1) IN2014CN04558A (OSRAM)
MX (1) MX355088B (OSRAM)
WO (1) WO2013078126A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN104582705A (zh) * 2012-01-10 2015-04-29 林伯士艾瑞斯公司 白介素-1受体相关激酶(irak)抑制剂和其用途
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN104902959A (zh) 2012-07-11 2015-09-09 林伯士艾瑞斯公司 Irak抑制剂和其用途
WO2014110114A1 (en) 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2015048281A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
JP7114076B2 (ja) * 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR20180075228A (ko) * 2016-12-26 2018-07-04 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019119206A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN108658999B (zh) * 2018-04-24 2021-02-05 温州大学 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
CN113272308B (zh) 2018-11-20 2025-03-18 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3725788A1 (en) 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
CN116410205B (zh) * 2021-12-29 2024-07-05 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法
CN116925098B (zh) * 2022-04-09 2026-02-17 深圳湾实验室 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用
WO2025085725A1 (en) * 2023-10-20 2025-04-24 Scorpion Therapeutics, Inc. Methods for treating a p53-associated cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080996A1 (en) * 2009-01-08 2010-07-15 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
EP1329454A1 (en) 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
CA2469316A1 (en) 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AR044743A1 (es) 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
AU2004247470B2 (en) 2003-06-11 2009-04-23 Xention Limited Thienopyrimidine derivatives as potassium channel inhibitors
US20050187389A1 (en) 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US7534767B2 (en) 2004-06-15 2009-05-19 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
WO2006010568A2 (de) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung
DE102005013621A1 (de) 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
CN101479274B (zh) 2006-04-26 2013-06-12 霍夫曼-拉罗奇有限公司 药用化合物
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
JP5500990B2 (ja) * 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
JP2011521941A (ja) 2008-05-30 2011-07-28 ミトロジクス Ａｎｔ−リガンド分子および生物学的アプリケ−ション
SI2493895T1 (sl) 2009-10-29 2017-10-30 Vectura Limited Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080996A1 (en) * 2009-01-08 2010-07-15 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
EP2782917A1 (en) 2014-10-01
IL232559B (en) 2018-04-30
ES2575143T3 (es) 2016-06-24
HK1202529A1 (zh) 2015-10-02
US20140323435A1 (en) 2014-10-30
MX2014006233A (es) 2014-10-17
AU2017203725A1 (en) 2017-06-22
US10183950B2 (en) 2019-01-22
IN2014CN04558A (OSRAM) 2015-09-18
US20190106433A1 (en) 2019-04-11
CA2855446A1 (en) 2013-05-30
NZ625447A (en) 2015-09-25
WO2013078126A1 (en) 2013-05-30
CN104053661B (zh) 2018-06-19
CA2855446C (en) 2021-04-20
CN104053661A (zh) 2014-09-17
JP6206926B2 (ja) 2017-10-04
JP2014533728A (ja) 2014-12-15
MX355088B (es) 2018-04-04
US10954251B2 (en) 2021-03-23
IL232559A0 (en) 2014-06-30
EP2782917B1 (en) 2016-03-02
EP3048106B1 (en) 2019-11-06
AU2012340869A1 (en) 2014-06-19
EP3048106A1 (en) 2016-07-27
AU2017203725B2 (en) 2019-02-28
US20170158706A1 (en) 2017-06-08
US9604994B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
AU2017203725B2 (en) Thienopyrimidine inhibitors of atypical protein kinase C
CA2886495C (en) Azaquinazoline inhibitors of atypical protein kinase c
US20240368167A1 (en) Heterobicyclic amides as inhibitors of cd38
EP3129372B1 (en) Azaquinazoline inhibitors of atypical protein kinase c
TW202128685A (zh) 作為ｆｇｆｒ抑制劑之雙環雜環
EP3398947B1 (en) Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof
AU2016286200B2 (en) Polycyclic amide derivatives as CDK9 inhibitors
WO2009049028A1 (en) Pyrrolopyrimidine compounds and their use as janus kinase modulators
AU2017260305B2 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
EP4003988A1 (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
HK1202529B (en) Thienopyrimidine inhibitors of atypical protein kinase c
NZ625447B2 (en) Thienopyrimidine inhibitors of atypical protein kinase c
WO2026044218A1 (en) Heterocyclic compounds as modulators of tnfa activity
WO2023009708A1 (en) Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors
WO2025230890A1 (en) 5,6 bicyclic heteroaromatic inhibitors of jak2
TW202602889A (zh) 可穩定苯丙胺酸羥化酶突變的化合物、藥物組合物及其用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED; IGNYTA, INC.

Free format text: FORMER APPLICANT(S): CEPHALON, INC.; CANCER RESEARCH TECHNOLOGY LIMITED

PC1 Assignment before grant (sect. 113)

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED

Free format text: FORMER APPLICANT(S): IGNYTA, INC.; CANCER RESEARCH TECHNOLOGY LIMITED

FGA Letters patent sealed or granted (standard patent)